| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening
|
Dekker, N.
|
|
2011
|
47 |
10 |
p. 1571-1577
7 p.
|
artikel
|
| 2 |
Adherence to national guidelines for treatment and outcome of endometrial cancer stage I in relation to co-morbidity in southern Netherlands 1995–2008
|
Boll, D.
|
|
2011
|
47 |
10 |
p. 1504-1510
7 p.
|
artikel
|
| 3 |
An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
|
Moehler, M.
|
|
2011
|
47 |
10 |
p. 1511-1520
10 p.
|
artikel
|
| 4 |
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies
|
Cohen, E.E.W.
|
|
2011
|
47 |
10 |
p. 1484-1489
6 p.
|
artikel
|
| 5 |
A randomised phase II trial of 1month versus 1year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients
|
Mao, Lili
|
|
2011
|
47 |
10 |
p. 1498-1503
6 p.
|
artikel
|
| 6 |
Couples’ communication before the wife’s death to cancer and the widower’s feelings of guilt or regret after the loss – A population-based investigation
|
Jonasson, Junmei Miao
|
|
2011
|
47 |
10 |
p. 1564-1570
7 p.
|
artikel
|
| 7 |
Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology
|
Gaultney, Jennifer G.
|
|
2011
|
47 |
10 |
p. 1458-1467
10 p.
|
artikel
|
| 8 |
Editorial board
|
|
|
2011
|
47 |
10 |
p. ii-
1 p.
|
artikel
|
| 9 |
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group
|
Koch, Andrea
|
|
2011
|
47 |
10 |
p. 1546-1555
10 p.
|
artikel
|
| 10 |
Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer
|
Otvos Jr., Laszlo
|
|
2011
|
47 |
10 |
p. 1578-1584
7 p.
|
artikel
|
| 11 |
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
|
Patel, Poulam M.
|
|
2011
|
47 |
10 |
p. 1476-1483
8 p.
|
artikel
|
| 12 |
Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature
|
Le Tourneau, Christophe
|
|
2011
|
47 |
10 |
p. 1468-1475
8 p.
|
artikel
|
| 13 |
Motor vehicle exposure and risk of oesophageal adenocarcinoma
|
Lagergren, Jesper
|
|
2011
|
47 |
10 |
p. 1446-1449
4 p.
|
artikel
|
| 14 |
One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients
|
Kawashima, Atsunari
|
|
2011
|
47 |
10 |
p. 1521-1526
6 p.
|
artikel
|
| 15 |
Peritumoural vascular invasion: A major determinant of triple-negative breast cancer outcome
|
Sabatier, Renaud
|
|
2011
|
47 |
10 |
p. 1537-1545
9 p.
|
artikel
|
| 16 |
Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy
|
Chinnaswamy, Girish
|
|
2011
|
47 |
10 |
p. 1556-1563
8 p.
|
artikel
|
| 17 |
Phase 1 trials of molecular targeted therapies: Are we evaluating toxicities properly?
|
Soria, Jean-Charles
|
|
2011
|
47 |
10 |
p. 1443-1445
3 p.
|
artikel
|
| 18 |
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44+CD24lo cancer stem cell phenotype
|
Reuben, James M.
|
|
2011
|
47 |
10 |
p. 1527-1536
10 p.
|
artikel
|
| 19 |
p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins
|
Yu, Huimei
|
|
2011
|
47 |
10 |
p. 1585-1594
10 p.
|
artikel
|
| 20 |
Reasons given by patients for participating, or not, in Phase 1 cancer trials
|
Catt, S.
|
|
2011
|
47 |
10 |
p. 1490-1497
8 p.
|
artikel
|
| 21 |
The preclinical and clinical activity of aviscumine: A potential anticancer drug
|
Zwierzina, Heinz
|
|
2011
|
47 |
10 |
p. 1450-1457
8 p.
|
artikel
|
| 22 |
VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients
|
Nagengast, Wouter B.
|
|
2011
|
47 |
10 |
p. 1595-1602
8 p.
|
artikel
|
Tijdschrift beschrijving